2016 News Releases

2016 News Releases

CSL CEO Says Holistic Approach to Business is Essential to Corporate Sustainability, the Company's Value Chain and Patients
21 Dec 2016

CSL released its 2015-2016 Corporate Responsibility Report, which details company performance in key social, environmental and economic priority areas.

Health Canada Approves CSL Behring’s AFSTYLA for the Treatment of Hemophilia A
14 Dec 2016

Health Canada has approved AFSTYLA, CSL Behring’s novel long-lasting recombinant factor VIII single-chain therapy for adults and children with hemophilia A.

CSL Behring Presents New Phase III Analysis of IDELVION® for Hemophilia B at the 2016 American Society of Hematology Annual Meeting
03 Dec 2016

Global biotherapeutics leader CSL Behring today announced new results from its Phase III clinical development program evaluating IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], the company’s novel, long-acting recombinant albumin fusion protein for the treatment of hemophilia B.

CSL Behring Presents Positive Results from the CSL112 AEGIS-I Phase 2b Trial
15 Nov 2016

AEGIS-1 Phase 2b study meets co-primary endpoints of hepatic and renal safety and demonstrates proof of mechanism - results were presented at AHA 2016.

AFSTYLA®, for Haemophilia A, Receives Positive Opinion from European Medicines Agency CHMP
14 Nov 2016

Global biotherapeutics leader CSL Behring announced today that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation for AFSTYLA® [Recombinant Human Coagulation Factor VIII, Single Chain] for patients with haemophilia A.